Clinical Trial Update: Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

View source ↗

Summary

This trial update presents long-term safety and efficacy observations for inhaled iloprost (Ventavis) in patients with primary pulmonary arterial hypertension o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Status: COMPLETED